oa GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum

References

1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:9753:1670–1681.
   [Google الباحث العلمي]
2. Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. J. Am. Coll. Cardiol. 2014; 63:25_PA:2889–2934.
   [Google الباحث العلمي]
3. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011; 32::1769–1818.
   [Google الباحث العلمي]
4. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can. J. Cardiol. 2013; 29::151–167.
   [Google الباحث العلمي]
5. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann. Intern. Med. 2013; 158:7:526–534.
   [Google الباحث العلمي]
6. Lambert G, Sjouke B, Choque B, Kastelein JJP, Hovingh GK. The PCSK9 decade. J. Lipid Res. 2012; 53:12:2515–2524.
   [Google الباحث العلمي]
7. Elguindy A, Yacoub MH. The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research. Glob. Cardiol. Sci. Pract. 2013; 4::1–5.
   [Google الباحث العلمي]
8. Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP. Article The Crystal Structure of PCSK9: A Regulator of Plasma LDL-Cholesterol. Structure. 2007; 15::545–552.
   [Google الباحث العلمي]
9. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type9 incombination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI57): a randomised, placebo-controlled, dose- ranging, phase2 study. Lancet. 2012; 380::2007–2017.
   [Google الباحث العلمي]
10. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol- lowering effects of AMG145, a monoclonal antibody to proprotein convertase subtilisin/ kexin type9 serine protease in patients with heterozygous familial hypercholesterolemia: theReduction of LDL-C with PCSK9 Inhibi. Circulation. 2012; 126::2408–2417.
    [Google الباحث العلمي]
11. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012; 308::2497–2506.
    [Google الباحث العلمي]
12. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial. Circulation. 2013; 129:2:234–243.
    [Google الباحث العلمي]
13. Urban D, Pöss J, Böhm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J. Am. Coll. Cardiol. 2013; 62:16:1401–1408.
    [Google الباحث العلمي]
14. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M. Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. J Am Coll Cardiol. 2014; 63:23:2541–2548.
    [Google الباحث العلمي]
15. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2014;, October. doi:10.1016/S0140-6736(14)61399-4.
    [Google الباحث العلمي]
16. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2014; October. doi:10.1016/S0140-6736(14)61374-X.
    [Google الباحث العلمي]
17. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R. Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial. JAMA. 2014; 311:18:1870–1882.
    [Google الباحث العلمي]
18. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. NEJM. 2014; 370:19:1809–1819.
    [Google الباحث العلمي]
19. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat. Rev. Cardiol. 2014; 11:10:563–575.
    [Google الباحث العلمي]
20. Larosa JC, Pedersen TR, Somaratne R, Wasserman SM. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. Am. J. Cardiol. 2013; 111::1221–1229.
    [Google الباحث العلمي]
21. Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, Joshi PH, Kulkarni KR, Mize PD, Kwiterovich PO, DeFilippis AP, Blumenthal RS, Jones SR. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J. Am. Coll. Cardiol. 2013; 62::732–739.
    [Google الباحث العلمي]